Episode
From sequence to scale: Gene editing’s new era in biologics manufacturing
- Podcast
- BioSpace
- Published
- Jul 10, 2026
- Duration seconds
- 1241
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biospace-6696251/from-sequence-to-scale-gene-editing-s-new-era-in-biologics-manufacturing.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jack Crawford , CEO, Demeetra Magnus Gustafsson , Chief Commercial Officer, NorthX Biologics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.